Ontamalimab
Phase 3Monoclonal antibody
TakedaOntamalimab is one of 70 biologic programs targeting Hepatitis. It is currently in Phase 3.
2
Indications
8
Total Trials
0
Active Trials
69
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
460 competitors in Ulcerative Colitis
#DrugCompanyPhaseTrials
1Omvoh
Eli LillyPhase 3
Velsipity
PfizerPhase 3
Jyseleca
GileadPhase 3
Skyrizi
AbbViePhase 3
Tremfya
Johnson & JohnsonPhase 3
Orencia
Bristol-Myers SquibbPhase 3
Mounjaro
Eli LillyPhase 3
Purinethol
SStason
Phase 3
Adtralza
LEO PharmaPhase 3
Valcyte
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Ulcerative Colitis4 trials
Moderate to Severe Crohn's Disease3 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ontamalimab. EMBL-EBI & Wellcome Sanger Institute.
- [4]